BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20656026)

  • 1. What is modulating solubility in simulated intestinal fluids?
    Ottaviani G; Gosling DJ; Patissier C; Rodde S; Zhou L; Faller B
    Eur J Pharm Sci; 2010 Nov; 41(3-4):452-7. PubMed ID: 20656026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethanol effects on apparent solubility of poorly soluble drugs in simulated intestinal fluid.
    Fagerberg JH; Al-Tikriti Y; Ragnarsson G; Bergström CA
    Mol Pharm; 2012 Jul; 9(7):1942-52. PubMed ID: 22651218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids.
    Clarysse S; Brouwers J; Tack J; Annaert P; Augustijns P
    Eur J Pharm Sci; 2011 Jul; 43(4):260-9. PubMed ID: 21570465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3.
    Fuchs A; Leigh M; Kloefer B; Dressman JB
    Eur J Pharm Biopharm; 2015 Aug; 94():229-40. PubMed ID: 26032292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of critical micellar concentration for the prediction of solubility enhancement in biorelevant media.
    Ottaviani G; Wendelspiess S; Alvarez-Sánchez R
    Mol Pharm; 2015 Apr; 12(4):1171-9. PubMed ID: 25665011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methodology for phase selection of a weak basic drug candidate, utilizing kinetic solubility profiles in bio-relevant media.
    Furukawa S; Zhao C; Ohki Y
    Eur J Pharm Biopharm; 2010 Feb; 74(2):298-303. PubMed ID: 19815062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissolution behavior of various drugs in different FaSSIF versions.
    Klumpp L; Leigh M; Dressman J
    Eur J Pharm Sci; 2020 Jan; 142():105138. PubMed ID: 31704344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excipient-mediated supersaturation stabilization in human intestinal fluids.
    Bevernage J; Forier T; Brouwers J; Tack J; Annaert P; Augustijns P
    Mol Pharm; 2011 Apr; 8(2):564-70. PubMed ID: 21268663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs.
    Schwebel HJ; van Hoogevest P; Leigh ML; Kuentz M
    Pharm Dev Technol; 2011 Jun; 16(3):278-86. PubMed ID: 20214530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids.
    Söderlind E; Karlsson E; Carlsson A; Kong R; Lenz A; Lindborg S; Sheng JJ
    Mol Pharm; 2010 Oct; 7(5):1498-507. PubMed ID: 20698569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biorelevant Drug Solubility Enhancement Modeled by a Linear Solvation Energy Relationship.
    Niederquell A; Kuentz M
    J Pharm Sci; 2018 Jan; 107(1):503-506. PubMed ID: 28864357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media.
    Fagerberg JH; Tsinman O; Sun N; Tsinman K; Avdeef A; Bergström CA
    Mol Pharm; 2010 Oct; 7(5):1419-30. PubMed ID: 20507160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery.
    Ibekwe VC; Fadda HM; Parsons GE; Basit AW
    Int J Pharm; 2006 Feb; 308(1-2):52-60. PubMed ID: 16356670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is bicarbonate buffer suitable as a dissolution medium?
    Boni JE; Brickl RS; Dressman J
    J Pharm Pharmacol; 2007 Oct; 59(10):1375-82. PubMed ID: 17910812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biorelevant solubility of poorly soluble drugs: rivaroxaban, furosemide, papaverine and niflumic acid.
    Takács-Novák K; Szőke V; Völgyi G; Horváth P; Ambrus R; Szabó-Révész P
    J Pharm Biomed Anal; 2013 Sep; 83():279-85. PubMed ID: 23770783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects.
    Vertzoni M; Fotaki N; Kostewicz E; Stippler E; Leuner C; Nicolaides E; Dressman J; Reppas C
    J Pharm Pharmacol; 2004 Apr; 56(4):453-62. PubMed ID: 15099440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small scale design of experiment investigation of equilibrium solubility in simulated fasted and fed intestinal fluid.
    McPherson S; Perrier J; Dunn C; Khadra I; Davidson S; Ainousah B; Wilson CG; Halbert G
    Eur J Pharm Biopharm; 2020 May; 150():14-23. PubMed ID: 32035969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Level Statistical Investigation of Equilibrium Solubility in Simulated Fasted and Fed Intestinal Fluid.
    Ainousah BE; Perrier J; Dunn C; Khadra I; Wilson CG; Halbert G
    Mol Pharm; 2017 Dec; 14(12):4170-4180. PubMed ID: 29072917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equilibrium drug solubility measurements in 96-well plates reveal similar drug solubilities in phosphate buffer pH 6.8 and human intestinal fluid.
    Heikkilä T; Karjalainen M; Ojala K; Partola K; Lammert F; Augustijns P; Urtti A; Yliperttula M; Peltonen L; Hirvonen J
    Int J Pharm; 2011 Feb; 405(1-2):132-6. PubMed ID: 21146596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gastrointestinal stability of lipid nanocapsules.
    Roger E; Lagarce F; Benoit JP
    Int J Pharm; 2009 Sep; 379(2):260-5. PubMed ID: 19524655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.